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COMMENTS
Rx: Just What the Doctor Ordered:
International Standards for Medical
Devices
Mindy H. Chapman*
I. INTRODUCTION: WHY ARE MEDICAL DEVICES MAKING
FRONT PAGE?
Medical devices have been a great source of private revenue and
public concern over the past decade.' The day after the birth of this
Comment, an eleven-day-old healthy baby was electrocuted to death
in a large United States hospital because of a design defect with an
infant breathing monitor.2 He was just one of many babies electro-
cuted by that medical device in the past eight years. In 1991, a Med-
line motor-driven feeding device was discovered to have so many
design defects that it caused electric shocks and over-feeding, result-
* I would like to thank Christina Martini, my editor, who left me with words of wisdom and
cut out the rest; Rosemary Gullikson, my classmate, for her encouragement; my parents, Marcia
and Marshall Tarre, for their blessings; my children, Emily and Daniel for their unbelievable
patience; and Richard Chapman, my husband and best friend, for his guidance and support dur-
ing this d~jh vu experience.
1 The Commerce Department declared that the three fastest-growing sectors of the United
States economy over the past five years were all in medical technology. Julie Kosterlitz, Device
Makers Get Up-Close-And-Personal, 1993 THE NAT'L J. 1968.
2 The design problem that would permit such a mistake was first detected in 1985 by the
U.S. Food and Drug Administration, which issued a nation wide warning after the electrocution
of several babies. (discussing the apnea monitor manufactured by Corometrics Medical Sys-
tems). Error Suspected in Baby's Death, CHI TRIB., Aug. 26, 1993, § News, at 1.
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ing in regurgitation, aspiration of fluids and death.3 In 1990, a Gen-
eral Electric magnetic resonance imaging machine was found to burn
patients.4 That same year, a blood sugar diagnostic device with multi-
ple design defects caused users to experience insulin shock or death.5
Even patients merely recuperating in electric hospital beds were in-
jured when design flaws resulted in beds breaking and falling.
6
Additionally, there has been much front page publicity about in-
jurious design defects with ventilators,7 defibrillators, s pacemakers,9
silicone breast implants, 10 back screws," and lasers used for eye sur-
gery. 2 Manufacturers sell these medical devices in the United States
and abroad. Although Congress has reacted to such catastrophes by
creating several new laws to regulate medical devices, it has failed to
diagnose accurately and treat the root of the problem. Currently, the
United States Food and Drug Administration (FDA) is considering
making changes to existing regulations. However, these proposed
changes again are inadequate to cure the ills of the American medical
device crisis.
Medical devices have existed in the United States since the late
1700's, when President George Washington bought brass and iron
3 THE GRAY SHEET, Sept. 16, 1991, at 22, available in LEXIS, GENMED Library, Gray
Sheet File (Medline recalls Dynafeed Enteral Feeding Pumps).
4 THE GRAY SHEET, Oct. 22, 1990, at I&W-5, available in LEXIS, GENMED Library, Gray
Sheet File (General Electric Signa Brand Magnetic Resonance Imaging System sold nationally
and internationally).
5 THE GRAY SHEET, Sept. 3, 1990, at 10, available in LEXIS, GENMED Library, Gray
Sheet File (Electronics Assembly Corporation manufactured the Blood Glucose Sensor).
6 THE GRAY SHEET, Aug. 25, 1986, at 10, available in LEXIS, GENMED Library, Gray
Sheet File.
7 Burnell Life Pulse Ventilators were used for critically ill infants. THE GRAY SHEET, Aug.
17, 1992, at 17, available in LEXIS, GENMED Library, Gray Sheet File.
8 THE GRAY SHEET, Aug. 25, 1986, at 10, available in LEXIS, GENMED Library, Gray
Sheet File (discussing Hewlett Packard defibrillator).
9 Device User Education, Product Quality are Linchpins of Action Plan III, Slated for Janu-
ary 1989 Implementation. FDA Commissioner Young Tells HIMA, THE GRAY SHEEr, Mar. 21,
1988, at 5, available in LEXIS, GENMED Library, Gray Sheet File (discussing Cordis Gamma
Series Pacemakers).
10 Geoffrey Cowley, Calling a Halt to the Big Business of Silicone Breast Implants, NEws-
WEEK, Jan. 20, 1992, at 56.
11 Nearly one in three back screws, which were used in spine surgery, broke due to design
defects causing patients permanent nerve damage. 20/20: The Secrets of the Back Screws-Crip-
pling Operations, (ABC television broadcast, Dec. 17, 1993)(discussing Steffe Back Screws man-
ufactured by Acromed Corp.).
12 Manufacturers Receiving Notice of Adverse Findings Letters for Failure to Submit MDR
Reports to FDA, THE GRAY SHEET, June 25, 1989, at 7, available in LEXIS, GENMED Library,
Gray Sheet File (discussing design defect found in Weck ophthalmic argon laser).
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rods to eliminate bodily diseases. 3 Over two hundred years later,
with the aid of complex technology, medical devices such as artificial
heart valves and kidney dialysis machines continue to prolong
thousands of lives each year. Medical technology has obviously
progressed over the centuries. Unfortunately, medical device regula-
tion has not kept up with these advances. To date, there are no
mandatory laws requiring all medical devices to demonstrate that
their design and materials are safe prior to sale.' 4 A great majority of
these design defects could be discovered and corrected if device man-
ufacturers were required to test every device's design and materials
adequately prior to marketing.' 5 Without the laws to require such
testing, manufacturers sell medical devices with disastrous design de-
fects. This in turn, as already noted, has led to serious injury and even
death.
By contrast, the newly emerging European Community has ac-
complished in only eight years what the United States has not
achieved in two hundred years. Despite the fact that the European
Community consists of twelve individual nations'6 with different lan-
guages, it had the foresight to gather its resources to remedy the prob-
lem, through legislation, before it surfaced. The European Commu-
nity's ex ante approach requires scrutiny of the design and materials
of all medical devices in the pre-production stage before launching
them on the manufacturing line.
This Comment demonstrates why the FDA should amend its
medical device regulations to emulate those of the European Commu-
nity. There are two major benefits of a single set of international stan-
dards. First, a single set of international standards assures safe
medical devices both in the United States and on the international
13 The device was eventually deemed fraudulent. Peter B. Hutt, A History of Regulation of
Adulteration and Misbranding of Medical Devices, 44 FoOD DRUG CosM. L.. 99, 100 (1988)
[hereinafter History].
14 Medical Devices; Current Good Manufacturing Practice (CGMP) Regulations; Revisions
Being Considered; Request for Information and Comments, 55 Fed. Reg. 24,544 (1990)(to be
codified at 21 C.F.R. § 820); THE GRAY SmEr, June 25, 1990, at 6, available in LEXIS,
GENMED Library, Gray Sheet File.
15 A study commissioned by FDA revealed that based on a random sample of one hundred
design-related incidents, "proper design controls would have prevented about 73% of the inci-
dents." Design Controls Would Apply to 16 Types of Class 1 Devices Under GMP Revision;
Requirements Regarding Qualifications of Consultants Also Suggested, THE GRAY SHnEr, Nov.
22, 1993, at 5, available in LEXIS, GENMED Library, Gray Sheet File.
16 France, Belgium, Luxembourg, Holland, West Germany, Italy, Denmark, Ireland, United
Kingdom, Portugal, Spain, and Greece. Mitzi Elkes, Europe 1992: Its Impact on Non Tariff
Trade Barriers and Trade Relations with the United States, 44 FoOD DRUG CosM. LJ. 563,566-67
(1989).
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market. Second, the United States will have a greater opportunity to
export medical devices to the newly prosperous European Commu-
nity resulting in greater financial returns and job opportunities for
Americans.
Part I of this Comment discusses the current federal legislation
governing the production of medical devices in the United States and
points out how the first vital link in ensuring public safety is missing
from the manufacturing chain. Parts II and III define medical devices
and describe the chronology of regulation in the United States. Part
IV discusses the history of the European Community and its con-
sumer policy approach to medical devices. Part V compares and con-
trasts the United States' and the European Community's approaches
to medical device regulations and the need for reform. Part VI
presents recommendations regarding future legislation for American
medical devices in light of the European Community's approach and
current FDA regulations. Part VII examines the drawbacks and bene-
fits of new legislation.
II. MEDICAL DEVICES: WHAT ARE THEY Now, AND WHAT NVERE
THEY BEFORE LEGISLATION?
A. Definition of Medical Devices
Medical devices pervade our health care experiences throughout
our entire lives, from fetal monitoring equipment and ultrasound
imaging before birth, to the life support systems and even suicide ma-
chines when death is imminent.
17
A medical device is defined as "any instrument, implant, or other
article recognized by the National Formulary or the United States
Pharmacopeia and designed to cure disease by affecting a patient's
physical structure or bodily function without relying principally on
some type of chemical action."'" Simply stated, devices include all
health care items other than drugs. 19
17 SUSAN B. FooTE, MANAGING THE MEDICAL ARMs RACE 3 (1992) [hereinafter
MANAGING].
18 21 U.S.C. § 321(h) (1993); David A. Kessler et al., The Federal Regulation of Medical
Devices, 317 NEw ENG. J. MED. 357 (1987); See, Phelps v. Sherwood Medical Industry, 836 F.2d
296 (7th Cir. 1987)(discussing heart catheter); Brooks v. Medtronic, Inc., 750 F.2d 1227 (4th Cir.
1984)(discussing heart pacemakers); Perfetti v. McGhan Medical, 662 P.2d 646 (N.M. Ct. App.
1983), cert. denied, 662 P.2d 645 (N.M. 1983)(discussing mammary prosthesis); Terhune v. A.H.
Robins Co., 577 P.2d 975 (Wash. 1978)(en banc) (discussing Dalkon shield intrauterine device);
MANAGING, supra note 17, at 9.
19 MANAGING, supra note 17, at 9.
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Medical devices range from the cutting edge of technology to the
mundane. Their scope encompasses the very complex such as artifi-
cial arteries,20 x-ray machines, and penile implants, to simple bedpans,
stethoscopes, and pregnancy test kits.2 ' Presently, the FDA regulates
approximately 1,800 types of medical devices.22 However, predictions
estimate that by the year 2000 there will be over 100,000 new and
improved medical devices on the market.3
B. The History of Medical Devices Prior to Federal Legislation
Although food, drug, and cosmetic products have been defined as
articles of commerce and therefore subject to government regulation
for centuries, medical devices have only recently been recognized as a
separate and distinct category of health products necessitating their
own unique form of government regulation.24
In ancient times, long before recorded history, simple medical de-
vices such as splints, wooden crutches, and rudimentary dental devices
were used by many cultures.25 By the eighteenth century, many
worthless medical devices were created by profit-driven swindlers.26
During the 1700's in Europe, "animal magnetism" medical devices
were sold to improve the buyer's health, but they were eventually
proven ineffective.27 At the same time, the first known medical device
was marketed in the United States to eliminate disease, but it was
eventually exposed as fraudulent.28 Many useless devices were on the
market, including one that claimed it could restore diseased organs
back to health by remote control!2 9 Despite the public's growing con-
20 Scientists have invented about sixty artificial body parts which have touched the lives of at
least eleven million Americans. Almost six percent of these patients have more than one im-
plant. Abigail J. Moss, et al., U.S. Dep't of Health and Human Services, Use of Selected Medical
Device Implants in the United States, 1988, 1988 DHHS PUBLICATION (PHS) 91-1250, Advance
Data No. 91 (1991) [hereinafter Use].
21 21 C.F.R. §§ 800-1299 (1993).
22 Agency Implements Safe Medical Devices Act; Food and Drug Administration, FDA CoN-
SUMER, Nov. 1991, at 5. The FDA has regulatory authority over a stunning $960 billion worth of
products which is twenty-five cents out of each consumer dollar spent. John Schwartz, Building
New Consensus To Improve Public Safety, THE WASH. POST, July 15, 1993, § 1, at A25.
23 MANAGING, supra note 17, at 4.
24 History, supra note 13, at 99.
25 History, supra note 13, at 99.
26 "Magneto-Conservative Garments" claimed to cure: "paralysis, kidney disease, liver dis-
ease, lung troubles, rheumatism, nervous prostration gout, stiff joints, locomotor ataxia, writers
cramp, loss of memory, giddiness, varicose veins, and every other form of disease." MANAGINO,
supra note 17, at 35.
27 History, supra note 13, at 99-100.
28 History, supra note 13, at 100.
29 MANAGING, supra note 17, at 36.
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cern over health and longevity, as evidenced by consumers' willing-
ness to buy these quack devices, there was no regulation of medical
devices. Still, even at this early point in American history, it would
appear to have been a sound idea to regulate devices to ensure their
safety and to protect consumers. However, this regulation did not
happen, and would not happen for a long time.
Surprisingly, the public and legislative spotlight focused only on
food and drugs. In the early 1900's, Congress enacted nationwide leg-
islation authorizing federal regulations of food and drugs. The first of
this legislation was The Biologics Act of 1902,30 sparked by the deaths
of ten St. Louis children from contaminated vaccines.31 Four years
later, Congress enacted The Pure Food and Drugs Act of 1906.32
However, this was watered down by compromises, amendments, and
adverse court rulings, and could only be weakly enforced by an inade-
quate government staff.33 Shockingly, the legislative history of the
1906 Act does not make any mention of medical devices,34 which ena-
bled medical device creators to continually exploit the sick but
hopeful.
3
A turning point for devices came in June 1933, when New Deal
legislation attempted to modernize and expand the 1906 Act.36 A
1933 report by the FDA first recognized that mechanical devices were
capable of extreme harm and, therefore, needed legislative controls.3 7
Five years later, Congress enacted the Federal Food, Drug and Cos-
metic Act of 1938 (Act),38 the first legislation to acknowledge and
regulate medical devices. Ironically, as soon as the Act was passed,
real problems began.
30 The Biologics Act of 1902, Pub. L. No. 57-244, 32 Stat. 728 (1902); History, supra note 13,
at 100.
31 Frank E. Young, A Golden Anniversary of Consumer Protection, FDA CONSUmR, June
1988, at 4.
32 The Pure Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat 768 (1906).
33 Young, supra note 31.
34 History, supra note 13, at 101.
35 By 1929, FDA had recognized problems due to lack of device regulations when it collabo-
rated with the United States Postal Office on seventy-three mail order medical device fraud
cases, including an insole device for the treatment of rheumatism and kidney disorders. History,
supra note 13, at 101.
36 History, supra note 13, at 102.
37 MANAGING, supra note 17, at 43.
38 The Federal Food, Drug and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (codified at
21 U.S.C. §§ 301-395 (1993)).
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III. THi HISTORY OF "REGULATED" MEDICAL DEvicEs
A. The Food Drug and Cosmetic Act of 1938
Superficially, it appeared as though the 1938 Act would put an
end to medical device problems. The Act provided the FDA with its
present statutory authority to take formal or informal regulatory ac-
tion against the adulteration or misbranding of food, drugs, devices
and cosmetics. The Act deems a device "adulterated" if it contains
filthy material, is prepared under unsanitary conditions or differs from
the quality represented in its labeling.39 Furthermore, the Act deems
a device "misbranded" if its labeling is false or misleading.4° The en-
forcement remedies available to the FDA include criminal prosecu-
tion of individuals and firms guilty of prohibited acts, injunctions
against such acts and seizures of adulterated or misbranded goods.41
The Act generally treated medical devices and drugs as similar
products. However, Congress made one significant distinction. Con-
gress deliberately separated the terms "medical devices" and "drugs"
when it added a pre-market notification requirement for the safety of
new drugs.42 Congress included this separate requirement in the legis-
lation because of a drug-related tragedy that killed more than one
hundred people the year before the Act was passed.43 Yet, Congress
did not add comparable pre-market notification provision for medical
devices.' Thus, although medical devices were the FDA's "children,"
it had no rules to enable them to safely cross the street to the
marketplace.
B. 1940's Through the Mid-1970's
For the next thirty-eight years, medical devices began shedding
their fraudulent reputation as they became more instrumental in the
39 Pub. L. No. 75-717, § 501, 52 Stat. 1049 (as amended 21 U.S.C. § 351).
40 Id.
41 The FDA has also relied on informal remedies not explicitly provided in the Act, such as
publicity, recalls, and regulatory letters: these now comprise the primary routine enforcement
tools of the agency. PETER B. Hurr & RicHARD A. MERRILL, FOOD AND DRUG LAW 12-13 (2d
ed. 1991); Ty pically, FDA enforcement annually results in 25,000 import detention, 8,000 "in-
spectional observations" of violations, and about 9,000 other measures, ranging from warning
letters to voluntary corrections, product recalls, seizures, injunctions, and criminal prosecution.
James S. Benson, FDA Enforcement Activities Protect Public, FDA CONSUMER, Jan.-Feb. 1991,
at 7.
42 History, supra note 13, at 104.
43 Elixir sulfanilamide, a new liquid form of the drug sulfanilamide, was tested for flavor,
appearance, and color, but not for safety: it killed over one hundred people. Young, supra note
31.
44 History, supra note 13, at 104.
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growth of health care technology. Following World War II, there was
a flood of new lifesaving medical devices sold in the market requiring
the FDA's attention.4' This period was so productive in the area of
medicine it was labeled the "therapeutic revolution."' As a result,
the FDA increased its effort to ensure the safety and effectiveness of
these new devices and to protect-the public against lingering fraudu-
lent devices.47 Still, there was no concern with the safety of device
design or its materials.
As medical technology soared, the line between drugs and medi-
cal devices blurred. In the 1960's, the judicial system struggled to de-
termine whether a medical treatment was a drug and therefore subject
to pre-market notification, or whether it was a device and thus virtu-
ally free from government scrutiny.48 This prompted the urgent need
to clarify the classification of borderline drugs used as medical devices
and to formulate regulations accordingly.
A second legislative turning point for medical devices came in
1970. Dr. Theodore Cooper, Director of the National Heart and
Lung Institute, completed a ten-year survey that revealed over 731
deaths and 9,000 injuries from medical devices.49 The Cooper Com-
mittee50 concluded that the breadth and diversity of new medical de-
vices presented entirely different issues from new drugs,5 and
recommended that the FDA take a different regulatory approach in-
45 History, supra note 13, at 106. Baxter Travenol provided a wartime success story when it
developed a container for blood collection and storage which allowed blood banking possible for
the first time. MANAGING, supra note 17, at 51.
46 Young, supra note 31; Even General Electric was inspired by the war and created portable
x-ray machines for use on ships and to screen new inductees for tuberculosis. MANAGING, supra
note 17, at 52.
47 History, supra note 13, at 106.
48 AMP Inc. v. Gardner, 389 F.2d 825 (2d Cir. 1968)(two nylon binding devices used to tie off
severed blood vessels during surgery were classified as new drugs and not devices); United States
v. An Article of Drug, 394 U.S. 784 (1969) (antibiotic disc that was used as a screening device in
the laboratory to determine the proper antibiotic to administer to patients and never came into
contact with the human body was classified as a drug and not a device).
49 Theodore Cooper, Device Legislation, 26 FoOD DRUG CosM. LJ. 165 (1971); MANAGING,
supra note 17, at 116.
50 "The Cooper Committee consisted of ten government officials-two from the FDA, five
from the various parts of the National Institutes of Health, and three from other parts of HEW."
History, supra note 13, at 109.
51 Devices and drugs are not substantially similar. Many devices are either invasive or im-
planted in patients for periods of time and pose a complex set of issues; pharmaceutical or bio-
logical agents are often given for limited time periods and can be withdrawn easily should
adverse events arise. David A. Kessler, Commissioner of Food and Drugs, Response to John
Dingell, Chairman, Subcommittee on Oversight and Investigations, U.S. House of Representa-
tives, Concerning Activities at the Center for Devices and Radiological Health, September 8,
1992, 3 FooD AND DRUG LAW REP. 12, at S-39 (1992).
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cluding a classification system based on risk for medical devices. The
Cooper Committee Report, along with administrative and legislative
activity of that time led to the enactment of the Medical Device
Amendments of 1976 (Amendments).52 For the first time, the
Amendments required that the FDA review the manufacturing
processes of medical devices before marketing. 3 Unfortunately, this
well-intentioned legislation was poorly planned, and created even
more regulatory chaos for medical devices.
C. The Medical Device Amendments of 1976
The primary purpose of the 1976 Amendments was to ensure that
new devices were safe and effective before sale. 4 The new regulations
categorized medical devices into "low,"55 "medium"56 and "high"
57
risk classes and outlined different routes a manufacturer could take to
market its product s.5  Additionally, the Amendments established the
current Good Manufacturing Practices (GMP) as general guidelines
for the manufacture, packaging, storage and installation of all finished
devices intended for human use.59 Moreover, the Amendments
52 The Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (1976)(codi-
fied at 21 U.S.C. § 360c-360k) [hereinafter Amendments].
53 Kessler, supra note 18.
54 Kessler, supra note 18. See Jonathan S. Kahan, Medical Device Reclassification: The
Evolution of FDA Policy, 42 FOOD DRUG CosM. W. 288 (1987); See Generally Robert Adler,
The 1976 Medical Device Amendments: A Step in the Right Direction Needs Another Step in the
Right Direction, 43 FOOD DRUG CosM. W. 511 (1988).
55 Low risk devices, Class I, include stethoscopes, powered toothbrushes, suction snakebite
kits, crutches, dental floss, and cold packs. 21 C.F.R. §§ 800-1299 (1993).
56 Medium risk, Class II, includes hearing aids, sickle cell tests, powered wheelchairs, rectal
dilators, and blood pressure cuffs. Id.
57 High risk, Class III, includes silicone gel-filled breast prosthesis, absorbable powder for
lubricating a surgeon's glove, infant radiant warmers, replacement heart valves and bone ce-
ment. Id.
58 A high risk device, Class III, must obtain FDA approval of a pre-market application
(PMA) before marketing the device. Food Drug & Cosmetic Act § 515(a)(codified at 21 U.S.C.
§ 360 e(a)); A high risk device on the market prior to the 1976 Act may remain on the market
pending an FDA regulation calling for PMA's to be submitted for that type of device. Food
Drug & Cosmetic Act § 515 (b)(1)(codified at 21 U.S.C. § 360e(b)(1)). However, if a new device,
regardless of risk status, is judged to be "substantially equivalent" to a device already on the
market prior to the 1976 Act, (or to a post-enactment device that has been found by FDA to be
substantially equivalent to a pre-enactment device) a sponsor need not obtain a PMA, but in-
stead may market the device after the submission of a pre-market notification, commonly re-
ferred to as a 510(k). Food Drug and Cosmetic Act § 510(k); 513(i)(codified at 21 U.S.C.
§§ 360(k), 360c(i)).
59 Established, July 1978, and has not been revised since initial promulgation. 21 C.F.R
§ 820.1.
574
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"grandfathered in"' many of the medical devices already on the mar-
ket which, in essence, allowed them to escape immediate government
scrutiny and to continue to be sold in the marketplace. Although the
Amendments established that such devices would eventually have to
prove safety and efficacy,6 they would not have to do so for well over
a decade.62
However, one final fatal legislative flaw remained: the FDA still
failed to require examination of medical devices in the pre-manufac-
turing stage. The agency did not require manufacturers to make a
prototype device and test its design and material under natural use
conditions prior to marketing. Therefore, the new federal regulation
allowed the manufacturing of medical devices with deadly flaws. Iron-
ically, by this time, American consumers finally felt more confident
that medical devices were safe for use when the FDA approved them.
D. Reactionary Regulations for Unsafe Medical Devices
Big problems with medical devices began to surface in the decade
following the Medical Device Amendments of 1976. For example, an
estimated sixty thousand to eighty thousand Americans received in-
sufficiently tested jaw implants for temporomandibular joint disorder
(TMJ).63 Such devices were supposed to relieve joint pain where the
jaw and skull connect. However, the devices legally dodged any seri-
ous regulatory evaluation because the FDA considered them similar
to jaw implants already on the market under the Amendments and,
therefore, grandfathered them into the stream of commerce without
any review. 64 The implant was breaking down and fragmenting as a
result of simple chewing.65 Consumers began to complain of pain in
60 "Grandfathering in" refers to a high risk device on the market prior to the 1976 Act which
was allowed to remain on the market pending an FDA regulation calling for Pre-Market Ap-
proval's (PMA's) for that type of device. Food Drug & Cosmetic Act § 515 (b)(1)(codified at 21
U.S.C. § 360e(b)(1)); In practice, FDA has required few PMA's for devices on the market prior
to the 1976 Act. Peter B. Hutt et al., The Standard of Evidence Required for Pre-market Ap-
proval Under the Medical Device Amendments of 1976, 47 FOOD AND DRUG LJ. 605, 607 n.16
(1992).
61 Food Drug and Cosmetic Act § 513 (a) (1) (codified at 21 U.S.C. §§ 360c(a)(1)-(2).
62 Food Drug & Cosmetic Act § 515 (b)(1)(codified at 21 U.S.C. § 360e(b)(1)). In the Safe
Medical Devices Act of 1990, Congress directed FDA, within a specified time frame, to evaluate
all high-risk devices on the market prior to 1976 where no regulation requiring a pre-market
approval application had been made. Hutt, supra note 60.
63 Judy Foreman, Danger Cited in Teflon Jaw Implants, BosrON GLOBE, June 5, 1992, at 11.
64 John Wilkins, For TMJ's Tortured Sufferers, Implants Cause Aching Regret, SAN DIEGO
UNION Tmn., July 25, 1993, at Al.
65Id
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the jaw and ear area, nausea,66 infections, dizziness, hearing and sight
loss.67 By 1984, one of the developers of the Vitek TMJ device re-
vealed that there were numerous reports of problems associated with
its device and admitted, "we have a calamity of unbelievable propor-
tions on our hands.,
68
The FDA soon reacted with more legislation. The FDA's Medical
Device Reporting Regulations of 198469 required manufacturers and
importers of medical devices to submit reports of death and serious
injuries associated with each device in addition to reports of poten-
tially harmful device malfunctions.70 However, this regulation left out
hospitals and health care facilities who only had a voluntary obligation
to report medical device problems. Consequently, those facilities sel-
dom reported such deaths or serious injuries because such reporting
was time consuming and optional.7'
Again, in an ex post fashion, the FDA promulgated the Safe
Medical Device Act of 1990 (SMDA)72 which made it mandatory for
the previously unregulated health care facilities and hospitals to re-
port medical device problems.73 The SMDA also required manufac-
turers to track implant patients so that they could be identified,
followed, and notified promptly of dangerous and defective devices.
However, two years later, Congress enacted the Medical Device
Amendments of 1992,71 which sadly delayed the SMDA tracking reg-
ulations.75 No new device laws have been enacted since then. How-
66 Anne Rochell, Implants 'A Health Fraud', ATLArA J. AND CONST., Sept. 25, 1993, at El.
67 Wilkins, supra note 64.
68 Philip J. Hilts, F.D.A. Issues Warning on Jaw Implants That May Disintegrate in the Body,
N.Y. TimEs, June 5, 1992, at A14.
69 49 Fed. Reg. 36,326-36,351 (1984).,
70 Since the reporting law took effect in 1984, the FDA has not only been inundated with
some 69,000 reports of medical device problems from manufacturers and importers, but it has
also seen the number of known problems reported annually skyrocket from around 2,500 to
between 18,000 and 20,000. Sana Siwolop, The Importance of Lobbying, FIN. WORLD, Aug. 21,
1990, at 58.
71 A 1986 GAO report estimated that only about fifty percent of device problems occurring
in hospitals were reported outside the hospital, and fewer than one percent were actually re-
ported directly to the FDA. U.S. Dep't of Health and Human Services, FDA Requires Health
Care Facilities to Report Death and Injury from Medical Devices, PuB. HEALTH REP., March-
June, 1992, at 238-39.
72 The Safe Medical Devices Act of 1990, Pub. L. No. 101-629, 104 Stat. 4511 (1990)[herein-
after SMDA]. SMDA required the establishment of an office to deal specifically with interna-
tional harmonization issues for medical devices. SMDA also gave authority to add pre-
production design validation controls to the device GMP regulations.
73 Physicians offices are exempt. SMDA, supra note 72.
74 Medical Device Amendments of 1992, Pub. L. No. 102-300, 106 Stat. 238 (1992).
75 THm GRAY SHEET, Aug. 16, 1993, at 5, available in LEXIS, GENMED Library, Gray
Sheet File.
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ever, there is currently a proposal by the FDA to require design
validation of medical devices.76 Disturbingly, it recommends that not
all devices should have to prove they are designed safely.
77
The Medical Device Reporting Regulations of 1984, Safe Medical
Device Act of 1990, and the recent Medical Device Amendments of
1992 all fail to locate and correct the root of the defective device prob-
lem. Although the cause of many of the device problems seems obvi-
ous, none of the laws require manufacturers to demonstrate that their
devices' design and materials are safe for consumers. And now,
although the proposed regulation looks like it is going in the right
direction, it is not going far enough.
E. The Aftermath of American Device Legislation: Current
Quality Problems in Medical Devices
Fortunately, American device legislation is not completely inept.
Recent device regulations require the health care industry to report
incidences of injury-causing devices to the FDA, and in turn, the FDA
reviews that data. A recent study reveals medical device manufactur-
ers filed reports for more than ninety-eight percent of all products that
were subject to serious recalls by the FDA.78 This statistic, however,
must be considered in light of the differences between the recalls of
devices due to violations of the manufacturing processes, governed by
the good manufacturing practices (GMP), and those due to design
flaws, not subject to regulations.
1. Good Manufacturing Practice Quality Problems
An FDA report disclosed that forty-seven percent of device-re-
lated quality problems were GMP-related violations, or deficiencies
which occur in the manufacturing phase.79 For example, intravenous
administration kits packaged with beetle-like insects are obviously not
76 58 Fed. Reg. 61,952 (1993) (to be codified 21 C.F.R. pt. 820) (proposed Nov. 23, 1993).
77 FDA is proposing to exempt ninety-five percent of Class I devices from proving design
validation. Design Controls Would Apply to 16 Types of Class I Devices Under GMP Revision;
Requirements Regarding Qualifications of Consultants Also Suggested, THE GRAY SHEET, Nov.
22, 1993, at 5, available in LEXIS, GENMED Library, Gray Sheet File.
78 Siwolop, supra note 70. The European Community does not file device incidence reports
like those filed with the FDA, and therefore comparable statistics are unavailable. Telephone
interview with George Lesser, Publisher, Europe Drug and Device Reports (Nov. 5, 1993).
79 Dep't of Health and Human Services, Public Health Service, Food and Drug Admin.,
HHS Pub. FDA 90-4235, Device Recalls a Study of Quality Problems, 4-6 (1990) [hereinafter
Recalls]; THE GRAY SHmET, April 30, 1990, at 10-11, available in LEXIS, GENMED Library,
Gray Sheet File.
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in compliance with the packaging regulations of the GMPs.80 In an-
other example, the Bjork-Shiley heart valve which has been implanted
in 86,000 patients worldwide, and is possibly responsible for nine hun-
dred deaths, malfunctions when a welded part fractures under the
stress of normal blood flow. 81 The company disclosed that most of the
malfunctioning valves were made by one employee.8 2 This disaster is
an example of a GMP violation of failure to control variations in the
manufacturing process.83 Manufacturers that violate GMP standards
are subject to the FDA's police powers.
2. Pre-Production Design Defects
However, the spotlight for proposed change is on a different area
of quality problems for medical devices. The same FDA report also
disclosed that forty-four percent of the quality problems that led to
recall action during the 1983-89 period were pre-production in nature
and caused by defects incorporated into the design or manufacturing
process during the design phase.84 Unfortunately, this pre-production
process is not subject to FDA regulations or police powers.
Clearly, the design phase is the single most important phase in
the life cycle of a device. 85 Without a good design, device perform-
ance cannot be improved, no matter how carefully a device may be
manufactured or how perfectly a GMP program is drafted.86 For ex-
ample, balloon catheters malfunctioned when fluids could not go
through them as designed. 87 The problem was due to the catheter's
blueprint, not the balloon material.88 This defect could have been
prevented if adequate care had been exercised in establishing physical
and operational requirements for the device including consideration
of the user and his environment.89 Testing should have been done
80 THE GRAY SHEET, May 21, 1990, at I&W-5-I&W-8, available in LEXIS, GENMED Li-
brary, Gray Sheet File.
81 Geoff Boucher, Engineer Says Test Proved Shiley's Valve's Value; Courts: Despite 'Devas-
tating' Results, The Device Was Not a Medical Failure, He Tells Jurors Hearing Recipient's Law-
suit, L.A. TiMEas, Aug. 28, 1993, at B8.
82 Id.
83 Recalls, supra note 79, at 8.
84 Recalls, supra note 79, at 3.
85 Device User Education, Product Quality are Linchpins of Action Plan III, Slated for Janu-
ary 1989 Implementation, FDA Commissioner Young Tells HIMA, THE GRAY SHEET, Mar. 21,
1988, at 5, available in LEXIS, GENMED Library, Gray Sheet File.
86 Id.
87 Recalls, supra note 79, at 5 (discussing Ingram Trocar catheters).
88 Recalls, supra note 79, at 5.
89 Recalls, supra note 79, at 5.
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before initiating the design effort, and certainly, before the release of
the design to production.'
Another example of pre-production design defects are compo-
nent design inadequacies. 91 Component design inadequacies include
selection of components that have inadequate strength or quality, and
are incompatible with other components, or the environment in which
the device is used.9z For example, catheters were recalled after it was
discovered that their hubs cracked when swabbed with alcohol.93 Evi-
dently, in selecting raw materials to be used for the hub, insufficient
consideration was given to conditions under which the catheter would
be used and the substances with which it would come in contact dur-
ing use.94 Such design defects could have been prevented by design
and material testing in the design phase. 5
A final example of defective designs is found in the computerized
software used in medical devices such as respirators, cardiac monitors
and ultrasound equipment. A study of software-related recalls from
1983 to 1991 indicated that over ninety percent of all software-related
device failures were due to design errors from failing to validate
software prior to routine production. 96 Alarmingly, there are numer-
ous medical device elements that need to be analyzed before produc-
tion. However, none of them are inspected until the manufacturing
stage. Generally, when the problems surface, the harm has already
occurred.
IV. THE EUROPEAN COMMUNITY AND ITS APPROACH TO
MEDICAL DEVICES
A. Overview: The European Community and Medical Devices
In sharp contrast to the United States, the European Community
has taken an ex ante approach to the problems associated with the
safety of medical devices. Unlike the United States, which allows de-
fectively designed devices on the market and later attempts to chase
them down and seize them, the European Community requires all
medical device manufacturers to demonstrate the testing of their de-
90 Recalls, supra note 79, at 5.
91 Recalls, supra note 79, at 5.
92 Recalls, supra note 79, at 5.
93 Recalls, supra note 79, at 5.
94 Recalls, supra note 79, at 5.
95 Recalls, supra note 79, at 6, 15; See generally THE GRAY SHEET, Mar. 21, 1988, at 5, avail-
able in LEXIS, GENMED Library, Gray Sheet File.
96 58 Fed. Reg. 61,952 (1993) (to be codified at 21 C.F.R. § 820) (proposed Nov. 23, 1993).
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signs and materials prior to market entry. No device in the European
Community escapes design validation testing.
B. The History of the European Community and Consumer
Legislation
The European Community97 was originally formed after World
War II to unite the nations of Western Europe and stimulate eco-
nomic recovery and growth.98 This goal became a formal political
event when these nations signed The Treaty of Rome99 in 1957 to es-
tablish the European Economic Community, also known as the "In-
ternal Market" or "Common Market."' 100 Under the Treaty of Rome,
the nations hoped to eliminate obstacles to the free movement of
people and resources by 1969.101 However, they did not achieve that
goal because of fiscal crises and a cumbersome bureaucratic infra-
structure. 102 Yet, by the end of that period, European Community
legislators recognized the need to protect consumers. 0 3 Due to orga-
nizational obstacles, the European Community took sixteen years to
achieve formal consumer legislation.
In 1985 consumer legislation was officially recognized in the Eu-
ropean Community when the "Commission's White Paper on Com-
pleting the Internal Market" was published."° It contained the "New
Approach to Technical Harmonization and Standardization," which
gave a new urgent priority to health and safety protection. 0 5 More-
over, it identified the national differences found in standards, legal
requirements of manufactured goods, manufacturing sophistication
and consumers' expectations, as genuine obstacles to free trade
among the member states.' 6 These problems were generally over-
97 France, Belgium, Luxembourg, Holland, West Germany, Italy, Denmark, Ireland, United
Kingdom, Portugal, Spain and Greece. Elkes, supra note 16, at 566-67.
98 Joseph Tretler, Jr., The Role of the American National Standards Institute in International
Device Standards, 45 FOOD DRUG COSM. LJ. 151, 152 (1990).
99 Treaty Establishing the European Economic Community, reprinted in TREATIES ESTAB-
LISHING THE EUROPEAN CoMMuNTYr 207 (1977).
100 Elkes, supra note 16, at 563.
101 Elkes, supra note 16, at 563.
102 Elkes, supra note 16, at 563.
103 In Paris, The Community Heads of State and Government declared that an improvement
in the quality of life must be the primary objective of economic development. This requirement
obviously necessitated a Consumer Policy. EC Commentaries, 1992 Coopers & Lybrand Eu-
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come two years later, in 1987 under the Single European Act" 7 which
focused on consumer protection. 08
C. The Single European Act
The Single European Act (SEA)10 9, also known as the "Blueprint
for 1992,"' 110 became effective on July 1, 1987, and amended the Treaty
of Rome."' The SEA incorporated the European Community's new
goals of creating a single internal market free of all trade barriers by
the end of 1992,112 and granting consumers a "high level of protec-
tion.""' 3 The European Community members realized that free trade
of products and services required certain standards, regardless of
where those products and services originated." 4 This philosophy also
carried over into the area of medical devices.
D. The European Community's Approach to Medical Devices
The European Community designed a unique and efficient sys-
tem for regulating medical devices. In 1992, the European Commu-
nity instituted "European Community Directives," which contain
broad "essential requirements" for groups of products," 5 but not the
specific standards the product must meet to get certified.116 The "es-
sential requirements" refer to the product itself, such as the materials
from which a medical device can be manufactured." 7 The Directives
propose that all medical devices must be certified according to a stan-
dard before the manufacturers can affix a "CE" mark to it." 8  A
"CE" mark, "Communaute Europeanne," indicates that all pertinent
107 Single European Act, reprinted in TR.AT-ns ESTABLISHING THE EUROPEAN COrMMUNrrY
1005 (1977).
108 Elkes, supra note 16, at 563.
109 Single European Act, supra note 107.
110 Elkes, supra note 16, at 568.
111 Tretler, supra note 98, at 153.
112 The Single Internal Market program is an ongoing process. Some changes were in effect
before 1992 and some were delayed until after 1992. Bob Straetz, European Community Single
Internal Market Opens, Bus. AM., Jan. 11, 1993, at 8.
113 Consumer Policy, supra note 103.
114 Gary Spizizen, The ISO 9000 Standards: Creating a Level Playing Field for International
Quality, 11 NAT'L PRODuCrlVITY REv. 331 (1992).
115 Consumer Policy, supra note 103; Michael J. Miller, U.S. International Standards Strate-
gies, 46 FOOD DRUG COSM. W., 311, 312 (1991).
116 Margaret L. Moses, Europe's New Product Safety Rule: Caveat Vendor, NJ.LJ., Dec. 28,
1992, at 11.
117 Spizizen, supra note 114, at 332.
118 U.S. Dep't of Commerce, Int'l Trade Admin., Medical Devices 3 (1993).
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European Community legal requirements for the product have been
met" 9 enabling sale in any member country.120
In general, the Directives impose an obligation on manufacturers,
distributors and importers to market only safe products. 12 1 Addition-
ally, they mandate informing the consumer of risks involved in the
product's application. 22 Whenever the use of the product may be
dangerous, the manufacturer must adopt measures to ensure consum-
ers will be informed of such risk. 23
European Community Directives on medical devices explicitly of-
fer the manufacturer a choice between two standards to demonstrate
that the product meets the "essential requirements" for product certi-
fication procedures. 24 One standard, the "type examination" is'a
traditional product certification which involves testing of the individ-
ual product itself. 23 The manufacturer must take each specific prod-
uct to the national test house of every member country. 126 For some
medical devices, clinical studies may be part of the process. This
"type" method may take up to one year' 27 to get a product certified in
various countries due to product complexity, testing method and cor-
respondence. This certification process is expensive and time
1281consuming.
The alternative standard attempts to eliminate the cumbersome
type examination. 129 This second standard under the Directives,
based on "quality assurance" techniques, 3 0 focuses on systems for
managing quality rather than on the product itself.131 Registration of
a quality system is intended to ensure that a comprehensive plan is in
place according to the original certified design specifications. 32 The
plan should detail the product's life from inception and testing,
119 Moses, supra note 116.
120 Consumer Policy, supra note 103.
121 Consumer Policy, supra note 103; Moses, supra note 116.
122 Moses, supra note 116.
123 Moses, supra note 116.
124 U.S. Dep't of Commerce, supra note 118.
125 March J. Laree, Wisconsin Firms Take ISO on the Road, CORP. REP. Wis., Aug. 1992, at
17; U.S. Dep't of Commerce, supra note 188.
126 Laree, supra note 125.
127 Laree, supra note 125.
128 Laree, supra note 125.
129 Laree, supra note 125.
130 U.S. Dep't of Commerce, supra note 118.
131 Quality standards are developed either in "response to inconsistencies that develop over
time in the manufacture of a particular product or in anticipation of a new product or service."
Spizizen, supra note 114, at 333.
132 Spizizen, supra note 114, at 333.
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through how it will be serviced during consumer use. Only accredited
agencies perform the required tests and issue certificates of conform-
ity133 authorizing a device to bear the "CE" mark. The European
Community Directives cite the International Organization for Stand-'
ardization 9000 series as a recommended standard for fulfilling quality
assurance requirements. 34
E. The International Organization for Standardization
The International Organization for Standardization (ISO) is a
treaty-based organization founded in 1947131 including over ninety
Member countries. 3 6 ISO encourages the international trade in
goods and services through the formation of global standards.137 The
standards use classical manufacturing technology to describe the es-
sentials of a sound quality-assurance system.' 38 The role of standardi-
zation provides a common ground and establishes a clear technical
language through which companies, industries and countries may
communicate.
39
The ISO 9000 Series standards were published in 1987.140 Forty
nations have adopted the Series, or a similar version, as their national
standards. 4 ' The ISO 9000 Series is not a European invention; many
countries outside of Europe, including the United States, participated
in the development process through ISO technical committees.14 2
Essentially, the standards require a third party, or a notified
body, to perform a "head-to-toe" examination of the entire produc-
tion process. These standards compel companies to document their
quality control systems at every step of the manufacturing chain by
identifying those areas that are causing quality control problems, and
correcting those problems before manufacturing and selling the prod-
uct.' 43 The ISO 9000 Series standards do not apply to specific prod-
133 They are also referred to as "notified" bodies. U.S. Dep't of Commerce, supra note 118,
at 4.
134 Moses, supra note 116.
135 James M. Gomez, O.C. Medical Device Companies Await Marketing Breakthrough in Eu-
rope; Sales: The Plan By 12 European Nations To Create Closer Economic 71es May Provide A
Bonanza For Local Firms, L.A. Tui~Es, Aug. 9, 1992, at D1.
136 Spizizen, supra note 114, at 333.
137 Spizizen, supra note 114, at 333.
138 Laree, supra note 125.
139 Tretler, supra note 98, at 153.
140 Spizizen, supra note 114, at 333.
141 Spizizen, supra note 114, at 333.
142 Spizizen, supra note 114, at 333.
143 James Callari, EC'92: Boon or Bust for U.S. Processors; Europe in 1992, PL.Asrxcs WORLD,
Jan. 1992, at 36.
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ucts, but are in effect, only a certification of the manufacturing
process.144
The Series consists of five sets of standards or criteria numbered
sequentially from 9000 to 9004.145 The ISO 9001, the most complex
standard, covers twenty production-related elements. 46 One critical
feature of the ISO 9001 is that it mandates pre-production design con-
trols requiring the manufacturer to demonstrate that the design and
the materials of the device are safe for its intended use,' 47an essential
element missing from the current FDA regulations.
The European Community, with exceptional foresight, pin-
pointed the origin of many medical device disasters and designed pre-
ventative legislation to avert such foreseeable tragedies by requiring
manufacturers to demonstrate that a device's design and materials are
safe for consumers before going to market. Sadly, the United States is
just starting to recognize that its regulatory system, originally set up
for medical devices over fifty years ago, and endlessly amended, is
disastrously deficient.
V. THE UNITED STATES' APPROACH TO MEDICAL DEVICES
COMPARED TO THE EUROPEAN COMMUNITY's APPROACH
A. Comparing and Contrasting the United States' Regulations to
the European Community's Device Directives
There are several superficial similarities between the United
States' and the European Community's approach to medical devices.
Both countries separate devices into three types of categories. The
American system, under FDA authority, divides all medical devices
into three classes based solely on consumer risk. Class III, the high-
est-risk devices are implantable devices such as breast, penile, and
heart valve implants. Class II consists of medium-risk devices such as
electrocardiographs, tracheostomy tubes, and neonatal incubators.
Class I contains lower-risk devices such as ice bags, tongue depressors,
and elastic bandages.
Similarly, the European Community classifies medical devices
into three categories; however, this division is based on product simi-
14 4 Mary Saunders, ISO 9000 and Marketing in Europe: Should U.S.Manufacturers Be Con-
cerned; European Quality System Standards, Bus. AM., April 20, 1992, at 24.
145 Spizizen, supra note 114, at 334.
146 ISO 9001 regulates twenty elements including training, marketing, design, purchasing,
contract review, corrective action and record keeping. Laree, supra note 125.
147 Revisions Being Considered to Current Good Manufacturing Practices (CGMP) for Medi-
cal Devices, 55 Fed. Reg. 24,544 (1990).
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larity and not on consumer risk. In the European Community, prod-
ucts are considered "regulated" or "unregulated," depending upon
whether there is a specific European Community Directive pertaining
to the particular product group.148 Regulated products, such as medi-
cal devices,'149 are those which affect health, safety or the environ-
ment.150 All regulated devices are divided into three specific
European Community Directives: (1) the Active Implantable Medical
Devices Directive (AIMD)' 51 which covers a small product area in-
cluding pacemakers; (2) the Medical Device Directive (MDD)
152
which covers the majority of all active and non-active devices; and (3)
the In Vitro Diagnostics Directive (IVD) 153 which covers reagents
154
and test kits.' 55 The European Community's Active Implantable
Medical Device Directive is the only category that has a correspond-
ing American category, Class III. Both classifications regulate im-
plant devices. The European Community's Medical Device Directive
and In Vitro Device Directive have devices that are classified in Class
I and Class II in the American system; however, since the systems are
based on different schemes, these two sets of categories are not di-
rectly comparable.
Although there are some commonalities between the American
approach and the European Community approach, there are substan-
tial differences. First, in the United States, a product can go to market
by demonstrating to the FDA that it is similar to another product on
the market prior to the 1976 Amendments. This "piggy-backing"' 56
process has proven dangerous because a new product with design
flaws can be approved for consumer use just because it is similar to a
product already on the market that may have the same design flaws.
As previously stated, this process has already permitted the sixty thou-
sand to eighty thousand defective jaw implants to enter the market
and harm innocent consumers. However, in the European Commu-
148 Moses, supra note 116.
149 Revisions Being Considered to Current Good Manufacturing Practices (CGMP) for Medi-
cal Devices, 55 Fed Reg. 24,544, supra note 147.
150 Spizizen, supra note 114.
151 The AIMD went into effect on Jan. 1, 1993 with a two year transition period. Michael
Fuchs, Medical and Dental Instruments and Supplies, U.S. INDUS. OUTLOOK, Jan. 1993, at 3.
152 The MDD is likely to go onto effect in early 1995 and will have a three year transition
period. Id.
153 Work has only begun on the IVD and it is likely to lag behind that of the MDD. Id.
154 A reagent, in chemistry, is a substance used to detect or measure another substance or to
convert one substance into another by means of the reaction which it causes. Id.
155 U.S. Dep't of Commerce, supra note 118, at 1.
156 Hrr & MERRILL, supra note 41, at 775.
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nity, in order to get a product in the market, the specific product or its
manufacturing process must demonstrate that it is in conformity with
European Community standards and must earn the "CE" mark. The
European Community laws simply inform manufacturers that if a de-
vice does not earn the "CE" stamp, it cannot be sold in the European
Community. Under either European Community method, every de-
vice or its processes are individually scrutinized and, unlike the United
States, cannot rely on the data of similar devices to escape govern-
ment scrutiny.
Second, although FDA is authorized to require the development
of performance standards for Class II and Class III devices, such de-
velopment is not mandatory and is left to the sole discretion of the
FDA according to agency priorities and resources. 7 As of today, the
FDA has virtually abandoned the idea of performance standards for
most medical devices. 8 By sharp contrast, the European Community
has offered device manufacturers a choice between two standards to
prove that their device meets the essential requirements. Although
the European Community standards seem superficially voluntary,
they are, in fact, required. The government funds the preponderance
of health care in Europe, therefore, conformity with standards are a
precondition for reimbursement of expenditures for devices by pub-
licly funded health care providers.'5 9 This makes compliance with
standards virtually mandatory.160 While the United States has merely
empowered the FDA with the authority to protect consumers, the Eu-
ropean Community has required that consumers are protected.
Third, there is a vast philosophical difference between the United
States' and European Community's public health policies towards
medical device consumers. Although the FDA finally conceded that
the medical device GMP should mandate pre-production design con-
trols to ensure quality devices and prevent consumer injuries, the re-
cent proposal suggests that such design controls should not apply to all
medical devices.' 61 Reprehensibly, this is the same mistake that Con-
157 21 U.S.C. § 3600)(1993).
158 Adler, supra note 54, at 514-15.
159 Richard F. Kingham, Regulation of Medical Devices in the European Community, 47 FOOD
AND DRUG L.J., 563, 564 (1992).
160 Id.
161 Proposed Revisions to Current Good Manufacturing Practices (CGMP) for Medical De-
vices, 58 Fed. Reg. 61,952 (1993) (to be codified at 21 C.F.R. § 820). The FDA did a cost/benefit
analysis and declared that, "the benefits from subjecting all the device establishments... to the
pre-production design elements were not great enough to justify the cost." The FDA is propos-
ing to exempt ninety-five percent of Class I devices from design controls. GMP Changes Add
$84.5 Mil. to Annual Industry Costs; FDA Says Increase Would be Offset by Public Health and
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gress made when it passed the 1976 Medical Device Amendments
which did not apply to all devices. Such gaping holes in the laws re-
sulted in dangerous devices already on the market remaining there
legally.
If the proposed GMP changes become law, there will still be mar-
ketable medical devices that are not required to demonstrate design
validity. Such partial legislation lacks foresight. We are approaching
the year 2000 when the modem technology of today will likely be
archaic. The drafters of the Food, Drug and Cosmetic Law of 1938 did
not anticipate such devices as breast implants and apnea monitors.
Similarly, it is shortsighted not to anticipate the innovative technology
of tomorrow. Therefore, it is critical that we place a standardized hur-
dle of safety for all future devices to jump over before they enter the
market place. If the proposed regulations are approved it will just be
another enormous legal loophole in the American device laws for in-
jurious devices to once again be legally sold to innocent consumers.
By contrast, the European Community requires that manufactur-
ers demonstrate that the design and materials of all medical devices
are safe for consumers prior to the manufacturing stage. The Euro-
pean Community, in its efforts to protect the consumers from all dan-
gerous devices, requires the product or its process to pass stringent
third-party inspections in order to earn the "CE" mark of conformity
to safety standards. This required symbol, which has no comparable
American counterpart, makes it easy for European Community con-
sumers to identify whether or not a device is legally on the market and
safe for use. By requiring all medical devices to be subject to the same
safety regulations, the European Community has quickly grasped a
valuable lesson from American legislative mistakes. Unfortunately,
the United States still does not comprehend the full message: No med-
ical device should evade government scrutiny before it reaches
consumers!
Lastly, the FDA's good manufacturing practice regulations for
medical devices are so weak and vague that they could apply to a vari-
ety of industrial goods. The regulations do not specify what type of
materials can or cannot be used for medical devices. Surprisingly, the
regulations do not even apply to manufacturers of components, or
parts of finished devices. 162 By contrast, the European Community
Economic Benefits, THE GRAY SHEET, Nov. 22, 1993, at 3-4, available in LEXIS, GENMED
Library, Gray Sheet File.
162 Proposed Revisions to Current Good Manufacturing Practices (CGMP) for Medical De-
vices, 58 Fed. Reg. 61,952, supra note 161.
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has gone to great lengths to clearly and specifically state the "essential
requirements" for the various medical devices. The essential require-
ments differ according to a device's intended use,163 such as what
materials may be used for various devices. However, the device's de-
sign and construction, including component parts, must be reviewed
prior to its sale."6 These key distinctions make the difference be-
tween the United States' vague and complicated approach, and the
European Community's comprehensive and clear approach to medical
device regulations. Unquestionably, these are life and death dis-
tinctions.
VI. FDA REGULATIONS SHOULD EMULATE THE EUROPEAN
COMMUNITY'S APPROACH
A. Introduction
The European Community Directives are far more definitive and
comprehensive in scope than the United States good manufacturing
processes. The European Community Directives have set the stage
for European consumers to purchase safer medical devices than
American consumers. However, medical device legislation in the
United States is well entrenched and cannot realistically be reformed
with fresh legislation like that adopted by the European Community.
To start over with a comprehensive new structure would have a monu-
mental impact on the resources of hospitals, patients, physicians, man-
ufacturers, legislators, FDA, Medicare, Medicaid and insurance
companies. Therefore, the United States can realistically only add
more "patchwork" regulations to the current laws. This section will
recommend new device regulations for implementing an international
standard within the current regulatory framework. The following sec-
tion will examine its perceived drawbacks and potential benefits.
B. Recommendations for Implementing an International Standard
1. Adopt ISO Standard Verbatim
FDA should adopt the ISO 9001 standard verbatim. This interna-
tionally accepted standard includes a pre-production design validation
requirement currently missing from American regulations. Addition-
ally, such adoption would provide for harmony of the United States'
and the European Community's standards. In turn, the European
Community will allow American imports of medical devices. On the
163 Kingham, supra note 159, at 568.
164 Kingham, supra note 159, at 566.
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other hand, if the United States does not adopt the European Com-
munity standards verbatim, the European Community will have rea-
son to restrict imports from the United States.
2. Mandate Pre-manufacturing Design Validation for All
Medical Devices
The United States should require all medical devices, regardless
of risk category, to conform to the same regulations so that there are
no loopholes for devices to slip through. The FDA should amend the
current GMP regulations to mandate manufacturers to demonstrate
that all devices presently on the market, regardless of class or level of
risk, have safe designs. Such an amendment is essential as a clean-up
effort for American devices to ensure that those devices already on
the market are safe with regards to their design, materials and compo-
nent parts. Since Congress started device legislation in the middle of
the manufacturing process, it is critical that the FDA requires that
manufacturers place pre-manufacturing controls not only on new de-
vices but on those already in the marketplace. There should be a tran-
sition period whereby device manufacturers must establish that their
device has been examined for design defects, and then they must sub-
mit a mandatory "Design Validation Report."
3. Collect User Fees as a Source of Revenue
User fees are the most efficient and equitable way to recover a
portion of the private benefit that industry derives from federal regu-
lation. There is a sound equitable rationale for user fees. Based upon
equity principles, an identifiable beneficiary of a government service
should at least pay the cost to the federal government of providing
that service. Such fees are currently imposed on drug manufacturers
seeking new drug approvals. 65 User fees are also employed in other
arenas. For example, user fees are imposed on tollway users for repair
expenses to keep the roads safe for travelers. Similarly, the profitable
device industry must pay for the services they are requesting from the
government. There are currently four untapped avenues for the FDA
to assess.
165 Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (1992). The
FDA expects it will hire about six hundred new employees with the resources from the fees,
which are expected to total more than $350 million over five years. Stuart L. Nightingale, M.D.,
Prescription Drug User Fee Enacted, 268 JAMA 3418 (1992).
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a. Design Validation Report User Fee for Devices Currently on
the Market
The FDA should require all manufacturers with devices currently
on the market submit a Design Validation Report along with a one-
time user fee. Like college or mortgage applications that require an
application fee, the FDA should charge an application fee to offset the
expenses incurred by additional reviewers.
b. Initiate User Fees for All New Medical Device Applications
Which Include the Design Validation Report
The FDA should require that manufacturers submit all new medi-
cal device applications with a non-refundable fee to the FDA in order
to pay for the time needed to review the general application, and spe-
cifically, the mandatory Design Validation Report.
c. Initiate User Fees for Medical Device Establishments
The FDA should require that all medical device establishments
pay an annual fee to be registered with the government. Such a regis-
tration fee should be applied towards FDA services rendered, includ-
ing consultations, reviews, inspectors, literature and other resources.
As of June 30, 1990, approximately 13,000 domestic and 4,500 foreign
medical device establishments were registered with FDA.166 There-
fore, an annual registration fee could result in valuable annual reve-
nues which could be used to offset the costs of FDA activities to
improve device safety.
d. Initiate User Fees on Medical Device Registrations
The FDA should require an annual registration fee for all FDA
approved medical devices. Medical devices must be registered in case
of recalls or safety alerts. The revenue from this fee should be
directed to safety activities, including an annual evaluation of prob-
lematic devices reported under the Medical Device Reporting Regula-
tions of 1984.
e. Spend User Fees Revenue on FDA Medical Device Sources
Only
All revenues collected by the FDA from medical device compa-
nies should be directed towards FDA device-related activities, such as
approvals, inspections, policy making and enforcement. Unless the
166 Hutt, supra note 156, at 785.
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FDA channels the device revenues into making the industry a safer
one for the public, there will be great resistance from medical device
manufacturing associations.
f. Differential Fee Assessment for Small or New Medical Device
Firms
Small and new medical device firms should be encouraged to ac-
cess the market since innovative ideas and jobs are essential to the
overall success of the program. Therefore, small and new firms should
be granted a discount on their user fees.
The government would have to establish working definitions for
the terms "small" and "new." The term "small" could either refer to
the number of devices that a firm manufactures, or to the number of
employees. A "new" firm could mean one that has been manufactur-
ing devices for less than a fixed number of years.
4. Evaluate Recall Standards Annually
The FDA should annually evaluate those medical devices that
cause injuries reported to the FDA under the Medical Device Report-
ing regulations of 1984.167 This evaluation should include statistics
about pre-manufacturing and manufacturing device problems, includ-
ing the type of injuries sustained. The FDA should analyze this infor-
mation in order to facilitate timely recalls of harmful devices.
VII. THE DRAWBACKS VS. THE BENEFITS
A. Overview of the Tension Between the Drawbacks and the
Benefits of Harmonized Device Standards
It is difficult to quarrel with government statistics that illustrate
the vast number of unsafe medical devices on the American market.
Device manufacturers admit that design validation is a healthy focus
for the industry. Yet, they argue the drawbacks outweigh the benefits.
However, the advantage of having safe and effective medical devices
on the market is not only economically favorable but is a just and
humane social policy. Additionally, harmony with European Commu-
nity device standards will not only afford American manufacturers
greater profits from exporting opportunities but will positively impact
other social and economic structures.
167 The most recent analysis of quality problems covers 1983-88 and the report was not avail-
able until 1990. Recalls, supra note 79.
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B. The Critics
1. More Regulations are Too Expensive
Critics of additional device legislation allege expenditures to
comply with any new regulations are too costly for manufacturers.
However, this is shortsighted. Device manufacturers have many sec-
ondary costs associated with defectively designed devices which result
in voluntary recalls, mandatory FDA seizures and exorbitant litigation
expenses. Moreover, if after a seizure or recall, the manufacturer
wants to keep its product on the market, it will inevitably need to
return to the drawing board to recreate a new design for the device or
replace it with better materials or components. Even the FDA con-
cedes benefits to the public health will easily exceed the cost of com-
pliance to new regulations. FDA calculated a manufacturers savings
of five million dollars per fatality avoided. 6 '
Initially, these recall or seizure costs include on-site inspections,
user notifications, and shipping or medical waste disposal expenses.
There are also re-manufacturing costs associated with redesigning the
device, purchasing new materials, re-tooling the factory, retraining
factory workers, re-educating salesmen, creating new sales literature
and discarding old inventory. The health care industry is a small
world, and the negative publicity of a recall adversely impacts sales
and the goodwill of the company. Further, those consumers seriously
injured from a device and unable to work become the financial re-
sponsibility of the taxpayers under the Social Security Disability pro-
gram. Most importantly, the company pays enormous litigation
expenses to defend a negligence or products liability lawsuit. Many
multi-million dollar awards and settlements169 result from defectively
designed devices. Additionally, courts may give plaintiffs punitive
monetary awards as high as three times the cost of the original jury
award if manufacturers market defective devices.1
70
168 GMP Changes Add $84.5 MiL to Annual Industry Costs; FDA Says Increase Would be
Offset by Public Health and Economic Benefits, TIE GRAY SHEET, Nov. 22, 1993, at 3-4, avail-
able in LEXIS, GENMED Library, Gray Sheet File.
169 There is a proposed $4.75 billion settlement fund for silicone gel-filled breast implant re-
cipients and individual settlements would range from $150,000 to $2 million. THE GRAY SHEET,
Sept. 13, 1993 at 1-3, available in LEXIS, GENMED Library, Gray Sheet File.
170 Currently, there are more than five hundred lawsuits seeking compensatory and punitive
damages totally more than four hundred million dollars against the manufacturer of the in-
trauterine device, Dalkon Shield. Hurr AND MERRILL, supra note 41, at 743; see generally Mor-
ton Mintz, The Dangers Insurance Companies Hide; Insurers Don't Have to Tell You When they
Know You Are About To Be Killed, Wash. Monthly, Jan. 1991 (discussing the Dalkon Shield).
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Initial costs of adapting to the proposed legislation are only short-
term expenses; the manufacturer will eventually prosper from the
long-term benefits. New standards can increase manufacturers' finan-
cial growth, because once their product is in harmony with the Euro-
pean Community standards, they can market it to the European
Community which is a nineteen billion dollar medical products mar-
ket, the second largest market behind the United States.' 7 ' Industry
analysts contend that the European Community is a "virtual hotbed"
for medical device sales. 172 Finally, a decrease in defective products
may result in substantially lower product liability rates for the manu-
facturer. Manufacturers who look only at today's costs foolishly miss
tomorrow sales.
Clearly, taking the time to validate a device's design will be a
more efficient use of resources. There will not only be a great deal of
financial savings with design controls, but such a policy will spare
manufacturers and consumers a great deal of pain and suffering.
2. New Standards are Burdensome to Implement
Manufacturers also claim that to comply with the ISO 9001 stan-
dards would be a "major effort.' 1 73 However, American device man-
ufacturers already comply with the ISO 9002 standards which begin
from the manufacturing phase of production. 74 Manufacturers would
not have to design a totally new system of manufacturing in order to
comply with the next standard, because ISO 9002 is a subset of ISO
9001.
3. Standards Should Remain Voluntary
Device manufacturers assert that the government should not
mandate quality.175 They want design validation activities to remain
171 The United States has the largest medical device market size, followed by the European
Community, Japan, and Canada. Mexico, Taiwan, Korea and Australia tied in market size after
Canada. Fuchs, supra note 151.
172 Gomez, supra note 135.
173 Ta GRAY SHEr, June 3, 1991, at 12-14, available in LEXIS, GENMED Library, Gray
Sheet File.
174 This includes manufacturing process controls, packaging process controls, equipment
maintenance, reprocessing controls, manufacturing material removal, environmental control, fin-
ished device storage, and problems attributable to employee error.
175 Silicone Implant Ruling not Popular with Industry, CHEM. MARKETING REP., Jan. 13, 1992,
at 4.
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voluntary and left to their own discretion.'76 Unfortunately, that mind
set created today's catastrophic situation.
Historically, the FDA counted on device manufacturing compa-
nies to carry out the necessary testing themselves, in an honest
manner. 77 Although the FDA scrutinized the results of the manufac-
turers research, it rarely demanded the raw data and instead, relied
upon the analyses and conclusions drawn by the company.178 The va-
lidity of data submitted by medical device companies to the FDA has
been increasingly questioned.
179
Clearly the "honor system" is a sham. It has left the United
States with injured consumers, bankrupt businesses and over-bur-
dened courts. There have been more than 1,300 deaths, and thousands
of serious injuries in the last decade alone resulting from the use of
FDA-approved drugs and medical devices.8 0 Manufacturers are often
blinded by ambiguous clinical data. It is easier for manufacturers to
focus only on the good aspects of the device, especially when there is
no impartial agency checking the results.
Lax regulation is still the far greatest danger to the public's
safety.' Regulation, after all, protects consumers from unscrupulous
business practices. 82 Therefore, design validation regulations must be
mandatory in order to compel compliance. Additionally, third-party
inspections, required under the ISO 9000 Series, will put an objective
police force at the plant.
4. There Should Be No Punitive Enforcement
Manufacturers not only want voluntary policy implementation,
but, if regulations are created, they do not want to be subject to puni-
tive actions. 183 The American device industry is a profitable market,
176 GMP Revision that Adopts ISO Standards Poses Some Problems, HIMA Says; Association
Recommends Development of "Approach" for Using ISO 9000, THE GRAY SHEEr, Mar. 11, 1991,
at 9-11, available in LEXIS, GENMED Library, Gray Sheet File.
177 Christine Gorman, Special Report: Drug Safety; Can Drug Firms Be Trusted?, TIME, Feb.
10, 1992.
178 Id.
179 Drug Approval Speedup Called Threat by HRG; Public Citizen Health Group, CHEM.
MARKETING REP., March 23, 1992, at 3.
180 Consumerists Say Approvals No Product Safety Guarantee, CHEM. MARKETING REP., May
21, 1990, at 9.
181 Barnaby J. Feder, F.D.A. to Investigate Safety of 5 More Medical Devices, N.Y. TMEs,
March 23, 1992, at D1.
182 Julie Kosterlitz, High-Wire Act, 22 NAT'L J. 1289 (1992).
183 GMP Revision that Adopts ISO Standards Poses Some Problems, HIMA Says; Association
Recommends Development of "Approach" for Using ISO 9000, THE GRAY SHEET, Mar. 11, 1991,
at 9-11, available in LEXIS, GENMED Library, Gray Sheet File.
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generating more than thirty billion dollars in sales a year. 84 During
the early 1990's, the United States was the largest producer, consumer
and exporter of medical devices.'" 5 Yet, there have been unprece-
dented reports of criminal or negligent activities by drug manufactur-
ers seeking approval for new medical devices. 86
Clearly, the industry does not have a clean record and the honor
system is a governmental disgrace. Consumers need to be protected
from the profit-motivated elements of manufacturers who do not want
to be punished for injuring the innocent consumer. Between the enor-
mous profits and the intense competition to bring new devices to the
$70.9 billion global market, there will be dirty hands unless there is
strict enforcement of device validation regulations."8 Congress must
implement such regulations with powerful enforcement tools such as
seizure, criminal contempt and treble damage awards.
C. Major Benefits of Additional Legislation
1. Safer Devices on the Market
The first step in producing a safe and effective medical device
begins in the design phase. Thoughtfulness paid to the plan and
materials of a medical device will increase the safety of that device's
design. The FDA concedes that if it implemented mandatory design
validation it would result in fifty-three fewer deaths and approxi-
mately 1,149 fewer serious injuries annually.18 8 This is an unequivocal
benefit to public health.
Logically, manufacturers examining a device under close scrutiny
discover problems that will occur during the everyday use of the prod-
uct. In order to insure that a design will be safe, its blueprint and
material must be tested in the setting in which it will be used. Had the
breathing device, mentioned at the beginning of this Comment, been
tested for flaws with the devices design, it would not have electrocuted
the eleven day-old healthy baby.8 9
184 Feder, supra note 181.
185 Gomez, supra note 135.
186 Drug Approval Speedup Called Threat by HRG; Public Citizen Health Group, CHEM.
MARKE rNG REP., March 23, 1992, at 3.
187 Fuchs, supra note 151.
188 GMP Changes Add $84.5 MiL to Annual Industry Costs; FDA Says Increase Would be
Offset by Public Health and Economic Benefits, THE GRAY SHEET, Nov. 22, 1993, at 3-4, avail-
able in LEXIS, GENMED Library, Gray Sheet File.
189 The shortcoming with the blueprint for the breathing devices that caused so many infants
to be electrocuted involved its connecting wires, called leads. Correctly used, a lead is attached
to the baby's chest and connected to the apnea monitor. Another lead is attached to a different
opening in the monitor and plugged directly into the electrical wall socket. The fatal design flaw
595
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The jaw implant device highlights the other area, where design
defects occur with regard to the material selected. The manufacturer
selected inferior material for use between the jaw and the skull which
could not withstand the constant use and pressure of the motions of
the mouth. Eventually, the material fragmented and migrated to the
skull, causing the user ceaseless, excruciating pain. This, in turn, re-
quired patients to undergo numerous surgeries to 'remove the device
and repair the joint. Disturbingly, the device's expected failure rate is
one hundred percent! 190 The substance selected for the TMJ device
could have effortlessly and inexpensively been examined by putting
the device in the TMJ joint of a test skull, and motorizing the jaw to
move and grind under the same pressure. Eventually, the material
would have fragmented in the laboratory without having to fragment
the lives of sixty thousand to eighty thousand consumers.
By contrast, the European Community's approach recognizes the
significance of ensuring that manufacturers design a device that is
compatible with its environment before production. The European
Community mandates that pre-production design validation must oc-
cur before the device gets to the manufacturing process, or to the con-
sumer. Although the European Community is still passing the laws
into effect, European consumers will no doubt benefit from the prior
experience of American legislative blunders.
Furthermore, the European Community has essentially barri-
caded itself against disastrous American devices because no device
can be sold on the European Community market without design vali-
dation and the CE seal of compliance. Additionally, the European
Community has mandated its safety requirements, instead of wasting
time and lives with a ludicrous voluntary system like that utilized in
the United States.
manifested itself when a busy or untrained user connected the two leads together without con-
necting them to the monitor. The plugs fit directly and easily together. Thus, the lead from the
baby's chest could be connected into the lead going directly into the electric outlet. This resulted
in a direct surge of electricity into the baby's body. This scenario is what an electric chair is
designed to accomplish. Ultimately, such an erroneous design begged for accidents.
This design flaw could have been readily detected if natural use investigations were man-
dated. If, in a pseudo-hospital or home setting, an experimenter was asked to use the device in
as many ways as possible, this defect would have inevitably surfaced. The answer, while still in
the pre-manufacturing stage, would have been to make the input/output connection incompati-
ble so that no direct attachment could possible be made. This is exactly what the manufacturer
did after tragically discovering the design defect during in vitro use. However, another fatal
mistake was made when the original leads were never taken off the market after the new ones
were manufactured. THE GRAY SHEET, Sept. 6, 1993, at 7, available in LEXIS, GENMED Li-
brary, Gray Sheet File.
190 20/20: After The Cure (ABC television broadcast, Oct. 8, 1993).
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2. Greater Exporting Opportunities to the European Community
The European Community is a significant player in the medical
device industry. Accordingly, American device manufacturers, with
foresight, can benefit from its presence. The mid-1990's represents an
opportunity for non-European companies to do business within the
European Community which has 345 million consumers and a $6.2
trillion market.' 91 Compliance with the ISO 9000 Series would make
it easier and quicker for American manufacturers to export their med-
ical devices to countries in the European Community. Manufacturers
will no longer need to alter products to meet a multiple set of local
standards,192 and instead will deal with one market rather than with
twelve.' 93 European Community physical barriers such as custom
controls and border formalities cost companies six billion dollars in
delays and red tape.' 9a This will decrease with the integration of Eu-
ropean Community member countries, 95 and ISO registration of
American products.
American medical device manufacturers with foresight are taking
advantage of the European Community changes by setting global fi-
nancial goals. 9 6 United States exports to the European Community
reached $3.4 billion in 1991, about sixty-one percent of total medical
device imports to that region.' 97 The European medical device mar-
ket presents tremendous opportunities for American companies to
maximize growth.' 98 Clearly, registration with ISO 9000 is a cost of
admission for doing business in Europe. 99 Therefore, ISO registra-
tion will be a must for any American company seeking the benefits of
191 Don Linville, Doing Business in the Single Market, Bus. AM., Mar. 8, 1993, at 20.
192 Elkes, supra note 16, at 563.
193 Steven M. Schneebaum, Products Liability in the European Community: What Does it
Mean for U.S. Companies?, 44 FOOD DRuG COSM. LJ., at 283 (1989).
194 Elkes, supra note 16, at 570.
195 Elkes, supra note 16, at 563.
196 Mary Wagner, The New Era in the European Marketplace, MOD. HEALTHCARE, Oct. 1,
1990, at 26.
197 Gomez, supra note 135.
198 Wagner, supra note 196. The European Commmunity has a large aging population with
corresponding medical problems. Medical device manufacturers who concentrate on the needs
of the elderly in America could benefit the elderly in the European Community as well as pro-
viding devices such as canes, hearing aids, and pacemakers. James M. Gomez, Medical Device
Companies Await Marketing Breakthrough in Europe; Sales: The Plan by 12 European Nations to
Create Closer Economic Ties May Provide a Bonanza for Local Firms, L.A. TIMES, Aug. 9,1992,
at D1.
199 Spizizen, supra note 114, at 331.
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the European marketplace.20 ° In competing against European suppli-
ers in the post 1992 European Community environment, an American
manufacturer who has not upgraded its system to ISO 9000 standards
will be at a competitive disadvantage.2 "1 A more consistent dedica-
tion to standards development would improve the United States posi-
tion in the international medical device arena .202 Medical devices
regulated by stringent European Community standards will almost
certainly be marketable anywhere else in the world.20 a Therefore,
changes in the American standards will not only open the door to the
European Community, but to Japan,204 Canada,205 and other coun-
tries.2°6 The prospects for exporting sales are enormous.
Additionally, such growth will correspond with creating new jobs
which will benefit the American economy. Employees will be needed
at all levels of manufacturing from the factory to the sales force. New
factories and office buildings will be needed which will boost the con-
struction business. Therefore, the new legislation will be a win-win
situation, not only for device manufacturers, but also for the labor
force and consumers.
Lastly, there is a beneficial domestic by-product of focusing on
international harmonization of device standards. Although many
companies still see the standards as a prerequisite for international
trade, more and more are discovering that, in fact, ISO compliance is
a factor in their United States business.20 7 Using ISO standards can
improve a company's marketing position because registration has be-
come a de facto marketing requirement in its particular industry.20 8
Where high product reliability is crucial, and two suppliers are com-
200 Jonathan B. Levine, Want EC Business? You Have Two Choices, Bus. WK., Oct. 19, 1992,
at 58.
201 Moses, supra note 116.
202 THm GRAY Si= r, Mar. 18, 1991, at 11-12, available in LEXIS, GENMED Library, Gray
Sheet File.
203 James Callari, EC'92: Boon or Bust for U.S. Processors; Europe in 1992, PLASmncs WoRLD,
Jan. 1992, at 36.
204 Japan has the largest single-nation market for medical products outside the United States.
Fuchs, supra note 151.
205 Canada has the second largest single-nation market, behind Japan, for medical products
outside the United States. Fuchs, supra note 151.
206 Mexico, Taiwan, Korea, and Australia share an identical market share behind Canada.
Fuchs, supra note 151.
207 Laree, supra note 125.
208 Laree, supra note 125.
Standards for Medical Devices
14:566 (1994)
peting for the same contract, the one with the ISO 9000 registration
may provide the needed competitive edge.
209
D. Further Beneficial Effects of New Legislation
1. International Exchange of Medical Technology
Another benefit of ISO 9000 registration is the international ex-
change of scientific information with foreign governments.210  As
scientists and physicians work together to develop harmonized device
standards, they will create an environment to share and relate new
medical information. As universal diseases become more complex,
the sharing of device technology will be even more critical to doctors
and their patients. This proposal will expedite scientific discoveries,
make better use of expertise and avoid duplication of work.
2. Decrease in Products Liability Litigation
The United States is a litigious society whose citizens are ready,
willing, and able to fie suit against anybody and everybody who
causes injury. Medical device litigation grew by seventy percent from
the 1960's through the 1970's, and continues to grow.211 During the
1990's, American judges and juries have awarded multi-million dollar
damage verdicts to medical device implant recipients.1 2 Additionally,
experts contend that legal costs would be in excess of one hundred
thousand dollars per case if each of the TMJ cases proceed through
the courts individually.213
Currently, there are 1,800 devices on the market, and with esti-
mates of over 90,000 new and improved devices coming into com-
merce by the year 2000, product liability litigation will explode unless
manufacturers pay attention to device designs. The chain reaction will
be devastating. Manufacturers will continue to purchase costly insur-
209 Mary Saunders, ISO 9000 and Marketing in Europe: Should U.S. Manufacturers Be Con-
cerned; European Quality System Standards, Bus. AM., Apr. 20, 1992, at 24.
210 Ti GRAY SHEEr, Jan. 25, 1993, at 6-7, available in LEXIS, GENMED Library, Gray
Sheet File.
211 John Agar, Labeling of Prescription Devices for the Food and Drug Administration and
Product Liability: A Primer-Part I, 45 FooD DRuG COsM. U., 447 (1990).
212 A jury awarded a forty-eight-year-old woman $8.6 million in damages because she devel-
oped connective cell disease when one of her breast implants ruptured. Some attorneys estimate
one thousand lawsuits pending against breast implant manufacturers. D'arcy Jenish et al., Beauty
and the Breast; Thousands of Canadian Women have Implants, and Many Now Fear the Effects,
MACLEAN HuNTmrR LiMrrD, Mar. 9, 1992, at 38.
213 Judge Approves Plan for Paying Vitek Tort Liability Claims, UPI, Oct. 22, 1989, available
in LEXIS, News Library, UPI File.
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ance, thus driving up the device price. This, in turn, hits the American
citizen, both as a consumer and taxpayer.
By contrast, if manufacturers scrutinize products in the design
phase for defects and alternative designs, there will be a natural de-
crease in injuries because less defective devices will be placed on the
market. Such activities will have a beneficial impact on decreasing
products liability in our society. Thus, the costs of devices will either
stabilize or decrease, benefitting consumers.
3. Manufacturing Benefits
There are also numerous documented manufacturing benefits
from adopting the European Community's ISO approach to medical
device legislation. Cost savings as a result of standardization will be
enormous.2 14 By consistently reviewing the entire manufacturing
chain, from pre-production through market use, actual production
costs are reduced as processes are refined.215 This review will
ultimately result in safer, less expensive products coming off the man-
ufacturing line. Additionally, increased consistency in production
processes, especially from shift to shift, will also reduce process devia-
tions and variability.216 Manufacturers consistently providing higher
quality products will result in less rework, less customer returns, and
less time spent solving customer problems.217 This will also reduce
costly inspections and warranty costs.218 Moreover, such reviews will
increase manufacturing yields.2"9 Finally, it will allow for better on-
time delivery resulting in more business 2 0 and bigger profits. Quality
consultants estimate that seventy percent of American companies, in-
cluding medical device companies, could improve by implementing a
quality system along the lines of the ISO standards.22 ' It is difficult to
argue with such success.
214 Elkes, supra note 16, at 572.
215 Spizizen, supra note 114, at 337.
216 Spizizen, supra note 114, at 337.
217 Spizizen, supra note 114, at 337.
218 Spizizen, supra note 114, at 337.
219 Spizizen, supra note 114, at 337.
220 Cyndee Miller, U.S. Firms Lag in Meeting Global Quality Standards, MARKENG NEws,
Feb. 15, 1993, at 1.
221 Laree, supra note 125.
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VIII. CONCLUSION
The medical device industry and the FDA cannot permanently
improve that which they cannot control.22 2 Lax legislation followed
by insufficient regulations of medical devices has actually harmed con-
sumers in numerous instances and, more importantly, has left consum-
ers vulnerable to potential injury in the future. As a result, the federal
government should require device firms to prove that a design is safe
before it is sold. Additionally, the United States government must
remedy previous mistakes by requiring medical devices currently in
the stream of commerce to submit design validation reports. It would
be a repeat mistake for the United States to treat certain medical de-
vices differently from others and to allow some to circumvent the pro-
posed design validation requirements. 223 Once again, the United
States has an opportunity to sew up the hole in medical device legisla-
tion. Hopefully, this will be the last repair.
222 March J. Laree, The Best & Worst of ISO 9000, CORP. REP. Wis., Aug. 1992, at 10.
223 58 Fed. Reg. 61,952, supra note 76.
